JAK2 and myeloproliferative neoplasm: Such dual approaches, which combine JAK2 inhibitors with Bcl-2/Bcl-xL inhibition, bromodomain inhibition, interferon-alpha, PI3K pathway, MAPK/ERK pathway inhibition, or others, are in clinical evaluation and highlight the significance as well as the promise of therapeutic developments in MPN [88,89,90,91,92,93].